- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
This Week in Managed Care: August 1, 2015
The announced price for alirocumab, the first PCSK9 inhibitor approved for use in the US, was the top story in managed care this week. Also, HHS announced $100 million available to combat substance abuse, and Medicare and Medicaid turn 50 years old.
The first PCSK9 inhibitor to combat bad cholesterol was approved for use in the US, and this week Sanofi and Regeneron set the wholesale price at $40 a day, which is well above what analysts had predicted. It is expected that payers, despite discounts, will strictly limit who gets the drug. A competitor, Amgen's evolocumab, may be joining the market by the end of the month.
Researchers determined that patients who receive a high number of prescriptions upon being discharged from the hospital are more likely to be readmitted within 30 days. Those who are readmitted are more like to be younger, African American, and have health problems such as heart disease, chronic obstructive pulmonary disease, diabetes, or metastatic cancer.
The government made a large number of funding available this week. HHS made $100 million in new funds available to combat substance abuse with a special focus on fighting opioid addiction. Plus, the Office of the National Coordinator announced it will award $38 million to 20 organizations to promote national efforts for better care, smarter spending, and healthier people.
And this week marked the 50th birthday of Medicare and Medicaid, the 2 largest healthcare payers in the country. The first Medicare recipient was former President Harry S. Truman, who received his card from President Lyndon B. Johnson at the signing ceremony in 1965. Currently, more than 55 million Americans are covered by Medicare.
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Data analysis showed that 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later; both Democrats and reproductive rights organizations are pressuring the Biden administration to ensure health insurers fully cover contraception; CMS implemented Medicare changes in March that limited access to blood tests that help transplant recipients ensure their organs remain healthy.
Read More
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen
The Impact of Nurse Practitioner Attribution in Medicare Shared Savings ACOs
December 5th 2023Allowing nurse practitioners to serve as attribution-eligible providers for Medicare Shared Savings Program accountable care organizations leads to no change in hierarchical condition category risk scores and modest growth in attributed beneficiaries.
Read More
